Zolbetuximab in gastric cancer has emerged as a promising targeted therapy for patients with CLDN18.2-positive disease. Recently, researchers conducted a real-world study to evaluate its efficacy and the physiological changes it triggers. This study focused on patients with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma. Furthermore, it explored whether early changes in serum albumin levels could predict treatment success or failure. Consequently, the findings provide valuable insights for oncologists managing this complex patient population.

Real-World Efficacy of Zolbetuximab in Gastric Cancer

The study cohort included 38 patients treated with zolbetuximab-based chemotherapy. Among the 24 patients with measurable disease, the objective response rate (ORR) reached an impressive 75.0%. Moreover, many patients achieved early tumor shrinkage within the initial cycles. These results align with those seen in previous phase 3 clinical trials. Therefore, the therapeutic benefit of zolbetuximab remains consistent in a real-world setting outside of strictly controlled environments.

Understanding Albumin Kinetics during Zolbetuximab Therapy

A common side effect during treatment is a decline in serum albumin. Many clinicians initially worried that this decline signaled treatment failure or poor nutrition. However, this study demonstrated that albumin kinetics do not correlate with antitumor efficacy. Specifically, both landmark nadir albumin and relative albumin changes showed no significant link to the ORR. Instead, these reductions likely represent a physiological response to the drug itself. Because of this, doctors should interpret early albumin drops as a manageable treatment-related change rather than a marker of progression.

In conclusion, the study reinforces the role of zolbetuximab as a potent treatment option. It clarifies that early albumin kinetics do not serve as surrogate markers for treatment failure. Consequently, clinicians should focus on overall clinical response and continue therapy despite minor biochemical fluctuations.

Does early albumin decline mean the treatment is failing?

No, the study shows that early reductions in serum albumin are common physiological changes. They do not correspond to impaired tumor response or reduced efficacy of the chemotherapy regimen.

Who is eligible for zolbetuximab-based chemotherapy?

Zolbetuximab is indicated for patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. Biomarker testing is necessary to confirm eligibility.

How does the real-world ORR compare to clinical trial data?

The real-world ORR of 75.0% observed in this cohort is consistent with the clinical benefits demonstrated in the pivotal SPOTLIGHT and GLOW phase 3 trials.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional opinion. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Ushimaru Y et al. Zolbetuximab-based chemotherapy in CLDN18.2-positive gastric cancer: real-world tumor response and early albumin kinetics. Jpn J Clin Oncol. 2026 Feb 13. doi: undefined. PMID: 41686471.


2. Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10388):1655-1668.


3. Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the phase 3 GLOW study. Nat Med. 2023;29(8):2133-2141.